EHA: AbbVie, Roche cement Venclexta's place in AML with survival win
ADA: Lilly’s Trulicity tops Ozempic at keeping patients compliant, real-world data show
ADA: Lilly's Trulicity tops Ozempic at keeping patients compliant, real-world data show
How to get to $11B? For Sanofi and Regeneron’s Dupixent, 5 new approvals would help
How to get to $11B? For Sanofi and Regeneron's Dupixent, 5 new approvals would help
ADA: AstraZeneca’s diabetes-fighter Farxiga cuts risk of fast decline in kidney function
ADA: AstraZeneca's diabetes-fighter Farxiga cuts risk of fast decline in kidney function
AbbVie’s Skyrizi bests Novartis’ Cosentyx in head-to-head psoriasis match
AbbVie's Skyrizi bests Novartis' Cosentyx in head-to-head psoriasis match
How to Handle the Pressure of Being a Manager Right Now
How to Handle the Pressure of Being a Manager Right Now
What Leadership Needs in the Decade Ahead
What Leadership Needs in the Decade Ahead
Alexion bets $1.4B on Portola and its laggard bleeding drug Andexxa
Alexion bets $1.4B on Portola and its laggard bleeding drug Andexxa
Novo’s Nash play takes shape
Novo’s Nash play takes shape
One Step Closer: FTC Clears AbbVie and Allergan’s $63 Billion Merger
One Step Closer: FTC Clears AbbVie and Allergan's $63 Billion Merger
